Publication Information

{'id': 'https://openalex.org/W2042930594', 'doi': 'https://doi.org/10.1097/00002030-200410210-00017', 'title': 'Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations', 'display_name': 'Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations', 'publication_year': 2004, 'publication_date': '2004-09-30', 'ids': {'openalex': 'https://openalex.org/W2042930594', 'doi': 'https://doi.org/10.1097/00002030-200410210-00017', 'mag': '2042930594', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/15577634'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1097/00002030-200410210-00017', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S20605092', 'display_name': 'AIDS', 'issn_l': '0269-9370', 'issn': ['0269-9370', '1473-5571'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'bronze', 'oa_url': 'https://doi.org/10.1097/00002030-200410210-00017', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5058603188', 'display_name': 'Daniel González de Requena', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Daniel González de Requena', 'raw_affiliation_strings': ['Pharmacology Unit and'], 'affiliations': [{'raw_affiliation_string': 'Pharmacology Unit and', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5082835290', 'display_name': 'Óscar Gallego', 'orcid': 'https://orcid.org/0000-0001-5665-0967'}, 'institutions': [], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Oscar Gallego', 'raw_affiliation_strings': ['Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.'], 'affiliations': [{'raw_affiliation_string': 'Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5031835893', 'display_name': 'Angélica Corral', 'orcid': 'https://orcid.org/0000-0001-5001-4679'}, 'institutions': [], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Angélica Corral', 'raw_affiliation_strings': ['Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.'], 'affiliations': [{'raw_affiliation_string': 'Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5105935726', 'display_name': 'Inmaculada Jiménez‐Nácher', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Inmaculada Jiménez-Nácher', 'raw_affiliation_strings': ['Pharmacology Unit and'], 'affiliations': [{'raw_affiliation_string': 'Pharmacology Unit and', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5009751300', 'display_name': 'Vincent Soriano', 'orcid': 'https://orcid.org/0000-0002-4624-5199'}, 'institutions': [], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Vincent Soriano', 'raw_affiliation_strings': ['Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.'], 'affiliations': [{'raw_affiliation_string': 'Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.', 'institution_ids': []}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.934, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 18, 'citation_normalized_percentile': {'value': 0.646739, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 85, 'max': 86}, 'biblio': {'volume': '18', 'issue': '15', 'first_page': '2091', 'last_page': '2094'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10526', 'display_name': 'HIV/AIDS drug development and treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2725', 'display_name': 'Infectious Diseases'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10526', 'display_name': 'HIV/AIDS drug development and treatment', 'score': 1.0, 'subfield': {'id': 'https://openalex.org/subfields/2725', 'display_name': 'Infectious Diseases'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10112', 'display_name': 'HIV Research and Treatment', 'score': 0.9992, 'subfield': {'id': 'https://openalex.org/subfields/2406', 'display_name': 'Virology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T12827', 'display_name': 'Biochemical and Molecular Research', 'score': 0.9952, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/efavirenz', 'display_name': 'Efavirenz', 'score': 0.9268291}, {'id': 'https://openalex.org/keywords/reverse-transcriptase-inhibitor', 'display_name': 'Reverse-transcriptase inhibitor', 'score': 0.6979017}, {'id': 'https://openalex.org/keywords/nucleoside-analogue', 'display_name': 'Nucleoside analogue', 'score': 0.46843275}], 'concepts': [{'id': 'https://openalex.org/C2781432083', 'wikidata': 'https://www.wikidata.org/wiki/Q422645', 'display_name': 'Efavirenz', 'level': 5, 'score': 0.9268291}, {'id': 'https://openalex.org/C156719811', 'wikidata': 'https://www.wikidata.org/wiki/Q28774', 'display_name': 'Reverse transcriptase', 'level': 4, 'score': 0.82385755}, {'id': 'https://openalex.org/C159047783', 'wikidata': 'https://www.wikidata.org/wiki/Q7215', 'display_name': 'Virology', 'level': 1, 'score': 0.7244768}, {'id': 'https://openalex.org/C2777351918', 'wikidata': 'https://www.wikidata.org/wiki/Q421559', 'display_name': 'Reverse-transcriptase inhibitor', 'level': 5, 'score': 0.6979017}, {'id': 'https://openalex.org/C2909970146', 'wikidata': 'https://www.wikidata.org/wiki/Q421559', 'display_name': 'Nucleoside Reverse Transcriptase Inhibitor', 'level': 5, 'score': 0.6956168}, {'id': 'https://openalex.org/C2777333352', 'wikidata': 'https://www.wikidata.org/wiki/Q2689559', 'display_name': 'Nucleoside analogue', 'level': 3, 'score': 0.46843275}, {'id': 'https://openalex.org/C2776543447', 'wikidata': 'https://www.wikidata.org/wiki/Q28734', 'display_name': 'Nucleoside', 'level': 2, 'score': 0.42768148}, {'id': 'https://openalex.org/C2522874641', 'wikidata': 'https://www.wikidata.org/wiki/Q808', 'display_name': 'Virus', 'level': 2, 'score': 0.4039654}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.3901345}, {'id': 'https://openalex.org/C2776452011', 'wikidata': 'https://www.wikidata.org/wiki/Q311463', 'display_name': 'Sida', 'level': 4, 'score': 0.34926653}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.3417213}, {'id': 'https://openalex.org/C2780727368', 'wikidata': 'https://www.wikidata.org/wiki/Q1928978', 'display_name': 'Viral disease', 'level': 3, 'score': 0.32964438}, {'id': 'https://openalex.org/C67705224', 'wikidata': 'https://www.wikidata.org/wiki/Q11053', 'display_name': 'RNA', 'level': 3, 'score': 0.21802807}, {'id': 'https://openalex.org/C142462285', 'wikidata': 'https://www.wikidata.org/wiki/Q2528140', 'display_name': 'Viral load', 'level': 3, 'score': 0.20675278}, {'id': 'https://openalex.org/C54355233', 'wikidata': 'https://www.wikidata.org/wiki/Q7162', 'display_name': 'Genetics', 'level': 1, 'score': 0.17766494}, {'id': 'https://openalex.org/C2993143319', 'wikidata': 'https://www.wikidata.org/wiki/Q583050', 'display_name': 'Antiretroviral therapy', 'level': 4, 'score': 0.16028336}, {'id': 'https://openalex.org/C104317684', 'wikidata': 'https://www.wikidata.org/wiki/Q7187', 'display_name': 'Gene', 'level': 2, 'score': 0.07162273}], 'mesh': [{'descriptor_ui': 'D024882', 'descriptor_name': 'Drug Resistance, Viral', 'qualifier_ui': 'Q000235', 'qualifier_name': 'genetics', 'is_major_topic': True}, {'descriptor_ui': 'D015658', 'descriptor_name': 'HIV Infections', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D015497', 'descriptor_name': 'HIV-1', 'qualifier_ui': 'Q000235', 'qualifier_name': 'genetics', 'is_major_topic': True}, {'descriptor_ui': 'D009154', 'descriptor_name': 'Mutation', 'qualifier_ui': 'Q000235', 'qualifier_name': 'genetics', 'is_major_topic': True}, {'descriptor_ui': 'D010078', 'descriptor_name': 'Oxazines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D018894', 'descriptor_name': 'Reverse Transcriptase Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000480', 'descriptor_name': 'Alkynes', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019380', 'descriptor_name': 'Anti-HIV Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019380', 'descriptor_name': 'Anti-HIV Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D048588', 'descriptor_name': 'Benzoxazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003521', 'descriptor_name': 'Cyclopropanes', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D024882', 'descriptor_name': 'Drug Resistance, Viral', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015658', 'descriptor_name': 'HIV Infections', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D015658', 'descriptor_name': 'HIV Infections', 'qualifier_ui': 'Q000097', 'qualifier_name': 'blood', 'is_major_topic': False}, {'descriptor_ui': 'D015497', 'descriptor_name': 'HIV-1', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009154', 'descriptor_name': 'Mutation', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019829', 'descriptor_name': 'Nevirapine', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}, {'descriptor_ui': 'D019829', 'descriptor_name': 'Nevirapine', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010078', 'descriptor_name': 'Oxazines', 'qualifier_ui': 'Q000097', 'qualifier_name': 'blood', 'is_major_topic': False}, {'descriptor_ui': 'D010078', 'descriptor_name': 'Oxazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D018894', 'descriptor_name': 'Reverse Transcriptase Inhibitors', 'qualifier_ui': 'Q000097', 'qualifier_name': 'blood', 'is_major_topic': False}, {'descriptor_ui': 'D018894', 'descriptor_name': 'Reverse Transcriptase Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D017211', 'descriptor_name': 'Treatment Failure', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019562', 'descriptor_name': 'Viral Load', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 3, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1097/00002030-200410210-00017', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S20605092', 'display_name': 'AIDS', 'issn_l': '0269-9370', 'issn': ['0269-9370', '1473-5571'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': True, 'landing_page_url': 'https://journals.lww.com/aidsonline/Fulltext/2004/10210/Higher_efavirenz_concentrations_determine_the.17.aspx', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/15577634', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1097/00002030-200410210-00017', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S20605092', 'display_name': 'AIDS', 'issn_l': '0269-9370', 'issn': ['0269-9370', '1473-5571'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.79, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 6, 'referenced_works': ['https://openalex.org/W1967914960', 'https://openalex.org/W2073157159', 'https://openalex.org/W2075881901', 'https://openalex.org/W2084136477', 'https://openalex.org/W2106737113', 'https://openalex.org/W2321852728'], 'related_works': ['https://openalex.org/W4240819394', 'https://openalex.org/W3129004714', 'https://openalex.org/W2582481590', 'https://openalex.org/W2318685045', 'https://openalex.org/W2318272070', 'https://openalex.org/W2116403346', 'https://openalex.org/W2074238145', 'https://openalex.org/W2051938714', 'https://openalex.org/W2015783657', 'https://openalex.org/W1988812212'], 'abstract_inverted_index': {'We': [0], 'examined': [1], 'the': [2, 17, 49, 99, 108, 129, 153, 182, 193, 209, 243, 306, 323, 350, 372, 401, 406, 444, 462, 486, 495, 531, 544, 599, 619, 777, 794, 961, 1030, 1037, 1061, 1065, 1070, 1093, 1106, 1120, 1154, 1157, 1188, 1202], 'influence': [3, 192], 'of': [4, 20, 34, 51, 101, 147, 155, 202, 211, 233, 245, 397, 464, 488, 533, 551, 569, 571, 601, 616, 621, 692, 748, 753, 761, 765, 912, 941, 947, 963, 1011, 1024, 1029, 1032, 1052, 1064, 1072, 1088, 1108, 1114, 1122, 1128, 1149, 1156, 1194], 'both': [5, 160, 234], 'efavirenz': [6, 21, 68, 93, 168, 185, 212, 235, 300, 458, 727, 804, 841, 873, 922, 944, 956, 1026, 1047, 1054, 1077, 1195, 1203], 'plasma': [7, 186, 236, 258, 317, 351, 367, 389, 558, 679, 702, 723, 728, 805, 842, 874, 878, 923, 945, 957, 1048, 1055, 1078, 1141, 1151, 1196], 'concentrations': [8, 187, 368, 390, 729, 806, 843, 875, 958, 1079, 1152, 1197], 'and': [9, 55, 62, 88, 162, 238, 335, 453, 582, 664, 672, 690, 698, 726, 734, 763, 793, 876, 921, 975, 983, 996, 1124, 1135], 'non-nucleoside': [10], 'reverse': [11, 77, 109, 310, 416], 'transcriptase': [12, 78, 110, 311, 417], '(NNRTI)': [13, 80], 'resistance': [14, 53, 178, 240, 437, 450, 476, 491, 589, 612, 784, 918, 1034, 1082, 1110, 1117], 'mutations': [15, 54, 103, 157, 179, 241, 477, 613, 785, 1118], 'on': [16, 149, 537, 780, 1173, 1185], 'antiviral': [18, 83], 'activity': [19, 84], 'in': [22, 141, 213, 242, 267, 461, 485, 494, 659, 687, 713, 741, 809, 897, 938, 1007, 1060, 1083, 1205], 'patients': [23, 35, 59, 142, 214, 255, 539, 609, 667, 823, 913, 942, 1012, 1089, 1115, 1166], 'experiencing': [24], 'early': [25, 216, 1015, 1062], 'virological': [26, 56, 194, 217, 345, 535, 655, 795, 810, 828, 932, 967, 1016, 1073, 1096], 'failure': [27, 218, 536, 1017, 1097], 'under': [28, 219, 283, 1018], 'nevirapine-containing': [29], 'regimens.': [30], 'Up': [31], 'to': [32, 191, 196, 206, 226, 443, 457, 481, 543, 708, 773, 817, 898, 1002, 1009, 1040, 1098, 1163, 1179, 1200, 1208], '41%': [33, 1010], 'reach': [36, 642], 'less': [37, 361, 948], 'than': [38, 70, 362, 844, 926, 949], '50': [39, 263, 363, 683], 'copies/ml': [40, 265], 'at': [41, 104, 279, 331, 393, 422, 598, 618, 668, 694, 730, 799, 812, 830, 869, 893, 972, 1119, 1153], '48': [42, 254, 976, 1003], 'weeks.': [43], 'No': [44], 'association': [45, 789], 'was': [46, 205, 248, 297, 320, 347, 355, 440, 459, 483, 523, 561, 604, 657, 685, 797, 867, 890, 969, 1027, 1043, 1067, 1101], 'found': [47, 798, 868], 'between': [48, 126, 790, 872], 'presence': [50, 463, 487, 792, 1031], 'NNRTI': [52, 117, 127, 177, 239, 475, 490, 588, 611, 1033, 1109], 'outcome.': [57], 'Nevertheless,': [58, 98, 159, 770, 1036], 'responding': [60], 'virologically': [61], 'carrying': [63, 175, 834, 914], 'NNRTI-resistant': [64], 'viruses': [65, 915], 'had': [66, 540, 624, 838], 'higher': [67, 808, 840], 'levels': [69, 237, 924, 946, 1056], 'those': [71, 845, 1165], 'who': [72, 256, 824, 846, 1013, 1167], 'did': [73, 640, 847], 'not': [74, 641, 848, 1132], 'respond.': [75], 'Non-nucleoside': [76], 'inhibitors': [79, 312], 'show': [81], 'high': [82, 1076], 'against': [85, 172], 'HIV-1': [86, 173, 415], 'infection,': [87], 'indirect': [89], 'evidence': [90], 'suggests': [91], 'that': [92, 123, 167, 740, 994], 'is': [94, 120, 128, 138, 1005], 'particularly': [95, 139], 'potent': [96], '[1–3].': [97], 'development': [100], 'single': [102], 'critical': [105, 953], 'sites': [106], 'within': [107], 'gene': [111], 'can': [112], 'reduce': [113], 'or': [114, 359, 467, 469, 472, 517, 586, 1138, 1177], 'even': [115], 'annul': [116], 'activity.': [118], 'It': [119], 'generally': [121], 'believed': [122], 'broad': [124], 'cross-resistance': [125], 'main': [130], 'factor': [131], 'limiting': [132], 'their': [133, 791], 'sequential': [134], 'use': [135, 210], '[4].': [136], 'This': [137, 887, 952, 1022], 'true': [140], 'failing': [143, 1090], 'for': [144, 278, 413, 525, 546, 575, 955], 'long': [145], 'periods': [146], 'time': [148, 396, 532, 550, 600, 620, 1121, 1155], 'NNRTI-based': [150, 197], 'regimens,': [151], 'when': [152, 349, 470], 'accumulation': [154], 'multiple': [156], 'occurs.': [158], 'in-vitro': [161], 'in-vivo': [163], 'studies': [164], 'have': [165, 188], 'suggested': [166], 'could': [169, 579, 1080, 1161, 1198], 'be': [170, 580, 737], 'effective': [171], 'strains': [174, 837, 920], 'some': [176], '[5,6].': [180], 'On': [181, 1092], 'other': [183, 474, 1094], 'hand,': [184, 1095], 'been': [189, 541], 'shown': [190], 'response': [195, 346, 656, 796, 829, 968, 1039], 'regimens': [198, 1100], '[7].': [199], 'The': [200, 231, 316, 555, 591, 701, 1050], 'aim': [201], 'this': [203, 246, 252, 638, 1041], 'study': [204, 743], 'determine': [207], 'whether': [208], 'showing': [215, 943], 'a': [220, 284, 292, 303, 378, 394, 547, 653, 751, 826, 899, 930, 965, 1019, 1084, 1181], 'nevirapine-based': [221, 285, 1020, 1099], 'regimen': [222], 'may': [223, 1168], 'allow': [224], 'them': [225], 'regain': [227], 'complete': [228, 995], 'viral': [229, 259, 352, 559, 602, 622, 680, 703, 718, 724, 879, 998, 1159], 'suppression.': [230], 'role': [232], 'effectiveness': [244], 'intervention': [247, 1042, 1066, 1183], 'also': [249, 970], 'analysed.': [250], 'For': [251], 'purpose,': [253], 'showed': [257, 929, 1014, 1136], 'load': [260, 353, 560, 681, 704, 719, 880], 'rebound': [261, 603, 623, 1160], 'over': [262, 356], 'HIV-RNA': [264, 318, 364, 565], '(confirmed': [266], 'two': [268, 308, 471, 758], 'separate': [269], 'specimens': [270], 'collected': [271], '2': [272], 'weeks': [273, 669, 695, 731, 779, 973, 1004], 'apart)': [274], 'after': [275, 338, 400, 776], 'being': [276], 'undetectable': [277, 678, 1139], 'least': [280], '3': [281, 927, 950, 1058], 'months': [282, 337, 553], 'triple': [286], 'combination': [287], '(nevirapine,': [288], '200': [289], 'mg': [290, 302], 'twice': [291], 'day)': [293, 304], 'were': [294, 329, 369, 391, 420, 478, 503, 745, 786, 807, 1131], 'selected.': [295], 'Nevirapine': [296, 366], 'substituted': [298], 'by': [299, 341, 651, 1046, 1105], '(600': [301], 'keeping': [305], 'same': [307, 407], 'nucleoside': [309], '(NRTI)': [313], 'as': [314, 412, 520, 750, 1125], 'backbone.': [315], 'level': [319], 'determined': [321, 370, 392], 'using': [322, 377, 405, 424, 505, 514], 'third-generation': [324], 'branched': [325], 'DNA': [326], 'assay.': [327], 'Measurements': [328], 'performed': [330, 441, 504], 'baseline,': [332], '3,': [333], '6': [334], '12': [336, 398, 832, 871], 'replacing': [339, 649], 'nevirapine': [340, 482, 596, 626, 650, 1140, 1150], 'efavirenz.': [342, 1186], 'A': [343, 567, 863], 'significant': [344, 654, 827, 865, 888, 931, 966], 'defined': [348], 'reduction': [354], '1': [357], 'log': [358, 722], 'reached': [360, 686], 'copies/ml.': [365, 566], 'before': [371], 'morning': [373], 'dose': [374, 403, 1204], 'intake': [375, 404], '(Ctrough)': [376], 'validated': [379], 'high-performance': [380, 408], 'liquid': [381, 409], 'chromatography': [382, 410], 'method': [383, 411], 'with': [384, 815, 916, 960, 1069], 'ultraviolet': [385], 'detection': [386], '[8].': [387], 'Efavirenz': [388], 'median': [395, 548, 556, 592], 'h': [399], 'night': [402], 'nevirapine.': [414, 1091], 'genetic': [418, 577], 'sequences': [419], 'obtained': [421], 'baseline': [423, 707], 'an': [425, 1206], 'automatic': [426], 'sequencer': [427], '(ABI': [428], '3000;': [429], 'Applied': [430], 'Biosystems,': [431], 'Foster': [432], 'city,': [433], 'CA,': [434], 'USA).': [435], 'Drug': [436], 'genotypic': [438], 'interpretation': [439], 'according': [442], 'latest': [445, 1189], 'International': [446, 496], 'AIDS': [447, 497], 'Society': [448, 498], 'USA': [449, 499], 'guidelines': [451], '(www.iasusa.org)': [452], 'expert': [454], 'advice.': [455], 'Resistance': [456, 480], 'considered': [460, 484, 524], 'either': [465, 515], 'K103N': [466], 'Y188L,': [468], 'more': [473, 587], 'present.': [479], 'any': [489, 800, 813], 'mutation': [492, 919], 'recorded': [493, 658, 712], 'list.': [500], 'Statistical': [501], 'analyses': [502], 'SPSS': [506], 'version': [507], '9.0': [508], '(SPSS': [509], 'Inc.,': [510], 'Chicago,': [511], 'IL,': [512], 'USA),': [513], 'parametric': [516], 'non-parametric': [518], 'tests': [519], 'needed.': [521], 'Significance': [522], 'P': [526, 859, 884, 905, 980, 987], 'values': [527], 'below': [528], '0.05.': [529], 'At': [530, 908], 'first': [534, 778, 1158], 'nevirapine,': [538], 'exposed': [542], 'drug': [545, 1147, 1175, 1192], '(range)': [549, 557], '7.4': [552], '(3–15).': [554], '4313': [562], '(72–45': [563], '148)': [564], 'total': [568], '29': [570], '35': [572], 'subjects': [573, 693], '(83%)': [574], 'whom': [576], 'material': [578], 'amplified': [581], 'sequenced': [583], 'harboured': [584], 'one': [585, 764], 'mutations.': [590, 1035, 1111], '(interquartile': [593], 'range;': [594], 'IQR)': [595], 'Ctrough': [597, 627], '3.6': [605, 852], 'μg/ml': [606, 631, 635, 853, 857, 928], '(2.4–4).': [607], 'Interestingly,': [608], 'lacking': [610], '(six': [614], 'out': [615, 739], '35)': [617], 'lower': [625], '[median': [628, 850], '(IQR)': [629, 851], '3.4': [630], '(2.05–4.05)': [632], 'versus': [633, 855, 978, 985], '0.03': [634], '(0–3.4)],': [636], 'although': [637, 757, 896], 'difference': [639], 'statistical': [643], 'significance': [644], '(P': [645], '=': [646, 860, 882, 885, 903, 906, 981, 988], '0.058).': [647], 'After': [648], 'efavirenz,': [652], '20': [660, 665], '(41.7%),': [661], '23': [662], '(48%)': [663], '(41.7%)': [666], '12,': [670, 696, 732, 910], '24': [671, 697, 733, 974], '48,': [673, 699, 895], 'respectively': [674], '(intent-to-treat': [675], 'analysis).': [676], 'An': [677], '(<': [682], 'copies/ml)': [684], '25,': [688], '39.6': [689], '41.7%': [691], 'respectively.': [700], 'reductions': [705], 'from': [706, 1170], 'each': [709], 'timepoint': [710, 814], 'are': [711], 'Table': [714, 820], '1.Table': [715], '1:': [716], 'Plasma': [717], 'changes': [720], '(Δ': [721], 'load)': [725], '48.It': [735], 'should': [736], 'pointed': [738], 'our': [742], 'there': [744], 'no': [746, 788], 'discontinuations': [747], 'therapy': [749], 'result': [752], 'efavirenz-related': [754], 'adverse': [755], 'effects,': [756], 'individuals': [759, 1130], 'complained': [760], 'dizziness': [762], 'vivid': [766], 'dreams': [767], 'plus': [768], 'insomnia.': [769], 'symptoms': [771], 'tended': [772], 'solve': [774], 'spontaneously': [775], 'therapy.': [781], 'When': [782], 'efavirenz-associated': [783, 835, 917], 'considered,': [787], 'timepoint.': [801], 'In': [802, 934, 1144, 1187], 'contrast,': [803, 935], 'responders': [811], 'respect': [816], 'non-responders': [818], '(see': [819], '1).': [821], 'Moreover,': [822], 'attained': [825], 'week': [831, 870, 894, 909], 'despite': [833], 'resistant': [836], 'significantly': [839], 'respond': [849], '(2.8–6.4)': [854], '2.7': [856], '(1.4–2.9);': [858], '0.027,': [861], 'respectively].': [862], 'positive': [864], 'correlation': [866, 889], 'Δlog': [877], '(r': [881, 902], '−0.4;': [883], '0.007).': [886], 'still': [891], 'present': [892], 'lesser': [900], 'extent': [901], '−0.41;': [904], '0.03).': [907], '75%': [911], 'greater': [925], 'response.': [933], 'it': [936], 'occurred': [937], 'only': [939], '22%': [940], 'μg/ml.': [951], 'threshold': [954], 'associated': [959, 1068], 'chance': [962], 'attaining': [964], 'confirmed': [971], '(79': [977], '40%;': [979], '0.03;': [982, 989], '76.4': [984], '41.6%;': [986], 'respectively).': [990], 'Our': [991], 'results': [992], 'demonstrate': [993], 'sustained': [997], 'suppression': [999], 'lasting': [1000], 'up': [1001, 1008], 'feasible': [1006], 'regimen.': [1021], 'benefit': [1023, 1169], 'taking': [1025], 'independent': [1028], 'initial': [1038], 'mainly': [1044], 'driven': [1045], 'concentrations.': [1049], 'attainment': [1051], 'adequate': [1053], '(>': [1057], 'μg/ml)': [1059], 'stages': [1063], 'chances': [1071], 'success.': [1074], 'Hypothetically,': [1075], 'overcome': [1081, 1209], 'relatively': [1085], 'large': [1086], 'proportion': [1087], 'almost': [1102], 'always': [1103], 'caused': [1104], 'selection': [1107], 'Only': [1112], '17%': [1113], 'lacked': [1116], 'failure,': [1123], 'expected': [1126], 'most': [1127], 'these': [1129], 'ot': [1133], 'compliant': [1134], 'low': [1137], 'trough': [1142], 'levels.': [1143], 'summary,': [1145], 'therapeutic': [1146, 1191], 'monitoring': [1148, 1193], 'help': [1162, 1199], 'identify': [1164], 'interventions': [1171], 'focused': [1172], 'improving': [1174], 'adherence': [1176], 'alternatively': [1178], 'attempt': [1180, 1207], 'rescue': [1182], 'based': [1184], 'situation,': [1190], 'optimize': [1201], 'resistance.': [1210]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2042930594', 'counts_by_year': [{'year': 2015, 'cited_by_count': 1}, {'year': 2014, 'cited_by_count': 1}, {'year': 2012, 'cited_by_count': 1}], 'updated_date': '2024-12-14T07:44:22.246085', 'created_date': '2016-06-24'}